Changes at Aspen cool down the profits

After a period of stellar growth, earnings from Africa's largest generic drugmaker, Aspen Pharmacare, are expected to cool in its full-year numbers this week because of restructuring. "The earnings numbers will not be poor, but they will not be as exciting as we have seen in the past because of the restructuring that they are going through," said Singa Gungqisa, retail analyst at Vunani Private Clients.